HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Research In Brief

This article was originally published in The Tan Sheet

Executive Summary

Acetaminophen mechanism of action: Analgesic may work by inhibiting COX-3 activity in brain and spinal cord, N. V. Chandrasekharan, et al., Brigham Young University, report in online Proceedings of the National Academy of Sciences posted Sept. 19. BYU researchers say they found a third distinct COX enzyme, which they named COX-3, derived from same gene as COX-1. Researchers tested common analgesic/antipyretic drugs and NSAIDS for their ability to inhibit COX -1, -2 and -3 activity in presence of exogenously added arachidonic acid at two concentrations. "At the higher concentration of substrate, only COX-3 was inhibited by acetaminophen. Moreover, COX-3 was significantly more sensitive to acetaminophen than either COX-1 or- 2 at the lower substrate concentration," Chandrasekharan et al. report. Researchers say their findings suggest that "highly selective inhibitors can be made for COX-3"...

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094564

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel